Сравнительная оценка зофеноприла: значимы ли для клиники особенности ингибиторов ангиотензинпревращающего фермента?
Аннотация
В статье дан обзор основных сравнительных исследований антигипертензивной эффективности и кардиопротективных свойств зофеноприла. Приведены данные о преимуществах препаратов с высокой тканевой доступностью в профилактике гипертрофии левого желудочка и повышения его жесткости, наличии у ряда препаратов антиатеросклеротических и антиишемических эффектов. Результаты приведенных исследований, раскрывая особенности действия препаратов данного класса, расширяют возможности практикующих врачей в лечении больных артериальной гипертензией с сопутствующей стенокардией, перенесших острый инфаркт миокарда.
Об авторе
А. А. Кириченко
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
Россия
Россия
Список литературы
1. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin - converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5 (9): 1965-77.
2. Mallion J.M. An evaluation of the initial and long - term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 13-8.
3. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press 2007; 2 (Suppl.): 25-30.
4. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 2 (Suppl.): 7-12.
5. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 2 (Suppl.): 19-24.
6. Malacco E, Piazza S, Omboni S on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175-82.
7. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin - converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42-54.
8. Weber K.T, Sun Y, Tuagi S.C, Cleutjens J.P. J Mol Cell Cardiol 1994; 26: 279-92.
9. Weber K.T, Sun Y, Dhalla A.K, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998; 37-44.
10. Gagnon C, Legault F, Geraldes P et al. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97 (3): 373-81.
11. Pasini A.F, Garbin U, Nava M.C et al. Effect of sulfhydryl and non - sulfhydryl angiotensin - converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443-50.
12. Napoli C, Bruzzese G, Ignarro L.J et al. Long - term treatment with sulfhydryl angiotensin - converting enzyme inhibition reduces carotid intima - media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1-8.
13. Borghi С, Ambrosioni E. Zofenopril: A Review of the Eevidence of its Benefits in Hypertension and Acute Myocardial Infarction. Clin Drug Invest 2000; 20 (5): 371-584.
14. Borghi С, Ambrosioni E, Magnani B. Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction. Am J Cardiol 1996; 78: 317-22.
15. Borghi С, Bacchelli S, Esposti D.D et al. Effects of an Angiotensin-Converting Enzime Ingibitor During the Acute Phase of Myocardial Infarction in Patients With Arterial Hypertension. Am J Hypertens 1999; 12: 665-72.
16. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin - converting enzyme inhibition in patients with non-ST- elevation acute anterior myocardial infarction. Am Heart J 2006; 152 (3): 470-7.
17. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long - term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post - myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long - term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7-14.
18. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther 2006; 4 (5): 631-47.
19. Borghi C, Ambrosioni E, Novo S et al. Оn behalf of the SMILE-4 Working Party. Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acidin Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Double-Blind, Parallel-Group, Multicenter, European Study (SMILE-4). Clin Cardiol 2012; DOI:10.1002/clc.22017.
20. Borghi C, Ambrosioni E, Omboni S et al. Cost - effectiveness of zofenopril in patientswith left ventricular systolic dysfunctionafter acute myocardial infarction: a posthoc analysis of SMILE-4. Clinico Economics and Outcomes Research 2013; 5: 317-25.
Рецензия
Для цитирования:
Кириченко А.А. Сравнительная оценка зофеноприла: значимы ли для клиники особенности ингибиторов ангиотензинпревращающего фермента?. Системные гипертензии. 2014;11(3):39-43.
For citation:
Kirichenko A.A. Comparative evaluation of zofenopril. Are the characteristics of angiotensin I converting enzyme inhibitors important for the practice? Systemic Hypertension. 2014;11(3):39-43. (In Russ.)
Просмотров:
101
Послать статью по эл. почте 